Compare KVYO & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | CRL |
|---|---|---|
| Founded | 2012 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.0B |
| IPO Year | 2023 | 2000 |
| Metric | KVYO | CRL |
|---|---|---|
| Price | $29.47 | $184.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 15 |
| Target Price | $43.17 | ★ $190.15 |
| AVG Volume (30 Days) | ★ 2.4M | 907.5K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,153,988,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $32.38 | N/A |
| Revenue Next Year | $21.60 | $1.66 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.81 | N/A |
| 52 Week Low | $23.44 | $91.86 |
| 52 Week High | $49.55 | $202.72 |
| Indicator | KVYO | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 62.56 |
| Support Level | $27.72 | $176.37 |
| Resistance Level | $28.89 | $186.72 |
| Average True Range (ATR) | 1.09 | 5.89 |
| MACD | 0.16 | 1.82 |
| Stochastic Oscillator | 72.82 | 92.60 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.